{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:54:28Z","timestamp":1780116868269,"version":"3.54.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1093\/annonc\/mdq024","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T05:49:43Z","timestamp":1265867383000},"page":"1877-1883","source":"Crossref","is-referenced-by-count":25,"title":["FDG\u2013PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study"],"prefix":"10.1016","volume":"21","author":[{"given":"E.","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Savelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bell\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Botto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Huglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq024_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(01)00127-5","article-title":"[18F]-FDG positron imaging in clinical management of lymphoma patients","volume":"38","author":"Talbot","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1093\/annonc\/mdq024_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0609.2008.01051.x","article-title":"PET\/CT in the management of haematological malignancies","volume":"80","author":"Hutchings","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdq024_bb0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"Wohrer","year":"2006","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdq024_bb0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","article-title":"Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin\u2019s lymphoma (NHL)","volume":"12","author":"Jerusalem","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdq024_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdq024_bb0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-Lopez","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1093\/annonc\/mdq024_bb0040","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.rlu.0000170086.45627.99","article-title":"FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy","volume":"30","author":"Joyce","year":"2005","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1093\/annonc\/mdq024_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5507\/bp.2007.020","article-title":"Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report","volume":"151","author":"Papajik","year":"2007","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1093\/annonc\/mdq024_bb0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1148\/radiol.2463060588","article-title":"B-cell non-Hodgkin lymphoma: PET\/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy\u2014initial experience","volume":"246","author":"Ulaner","year":"2008","journal-title":"Radiology"},{"issue":"1","key":"10.1093\/annonc\/mdq024_bb0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2967\/jnumed.108.055376","article-title":"18F-FDG PET\/TC for monitoring the response of lymphoma to radioimmunotherapy","volume":"50","author":"Jacene","year":"2009","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1093\/annonc\/mdq024_bb0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/RLU.0b013e3181596652","article-title":"Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan","volume":"32","author":"DeMonaco","year":"2007","journal-title":"Clin Nucl Med"},{"key":"10.1093\/annonc\/mdq024_bb0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1093\/annonc\/mdq024_bb0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","article-title":"EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Tennvall","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdq024_bb0075","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdq024_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq024_bb0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdq024_bb0090","first-page":"163","article-title":"Evaluation of survival data and two new rank order arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/annonc\/mdq024_bb0095","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq024_bb0100","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomised controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdq024_bb0105","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq024_bb0110","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/mdq024_bb0115","first-page":"560","article-title":"Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]","volume":"23","author":"Shipley","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdq024_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1093\/annonc\/mdq024_bb0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejca.2007.12.008","article-title":"Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice\u2014report of a European workshop","volume":"44","author":"Zinzani","year":"2008","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdq024_bb0130","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of phase \u00bd study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq024_bb0135","first-page":"585","article-title":"Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade follicular, and transformed non-Hodgkin's lymphoma (NHL)","volume":"23","author":"Gregory","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdq024_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.47.43","article-title":"Radioimmunotherapy for non-Hodgkin lymphoma: historical prospective and current status","volume":"47","author":"Emmanouilides","year":"2007","journal-title":"J Clin Exp Hematopathol"},{"issue":"21","key":"10.1093\/annonc\/mdq024_bb0145","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin\u2019s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq024_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419400495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419400495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/9\/1877\/13783325\/mdq024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:37:36Z","timestamp":1624700256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419400495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0923753419400495"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq024","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}